Drug Profile
Research programme: CCR2 antagonists - Bristol-Myers Squibb
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Benzamides; Cyclohexenes; Cyclohexylamines; Small molecules
- Mechanism of Action CCR2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Inflammation in USA
- 07 Apr 2013 Early research is ongoing in USA
- 01 Sep 2011 Early research is ongoing in USA